Abbott Laboratories has shown strong performance in the US medical device market, with modest changes in average selling prices (ASPs) and continued growth in key product lines. Abbott’s ASPs have slightly declined in the first six months of 2025 when compared to reports from the same period in 2024 for some high-volume product lines. Focusing on the broader trend, Abbott’s top revenue-generating products have maintained consistent ASP across 2024 and 2025, indicating that its core offerings remain well-positioned and resilience to difficult economic situations, such as those brought on by developing tariff policies, according to GlobalData.
Thomas Fleming, Medical Analyst, GlobalData, comments, “When analysing Abbott’s highest-volume products, some nuances emerge. Products that ranked highest by volume of sales in 2024 experienced modest increases in ASP, while those leading by volume in 2025 showed no change or a slight decline in ASP. This pattern may reflect changing purchasing strategies among US healthcare facilities, potentially arising due to evolving priorities in public health and cost considerations.”
According to its recent financial report, Abbott delivered a strong first half in 2025, with its US medical device sales growing by 14.8 per cent compared to H1 2024. GlobalData’s latest data indicates continued strong performance across several key product lines, including MitraClip, Ensite X, and Tactiflex. In the US cardiovascular market, Abbott holds approximately 18 per cent market share, according to GlobalData.
Abbott’s US diagnostics have seen a modest decline in year-over-year sales in Q2 2025, specifically in point-of-care and rapid diagnostics.
Fleming concludes, “This appears to be linked to reduced demand for COVID-19 testing, which had previously seen high demand. This shift in demand could be responsible for the changes in Abbott’s high-volume sales.”